Literature DB >> 22685298

Serine phosphorylation of the insulin-like growth factor I (IGF-1) receptor C-terminal tail restrains kinase activity and cell growth.

Geraldine M Kelly1, Deirdre A Buckley, Patrick A Kiely, David R Adams, Rosemary O'Connor.   

Abstract

Insulin-like growth factor I receptor (IGF-1R) signaling is essential for cell, organ, and animal growth. The C-terminal tail of the IGF-1R exhibits regulatory function, but the mechanism is unknown. Here, we show that mutation of Ser-1248 (S1248A) enhances IGF-1R in vitro kinase activity, autophosphorylation, Akt/mammalian target of rapamycin activity, and cell growth. Ser-1248 phosphorylation is mediated by GSK-3β in a mechanism that involves a priming phosphorylation on Ser-1252. GSK-3β knock-out cells exhibit reduced IGF-1R cell surface expression, enhanced IGF-1R kinase activity, and signaling. Examination of crystallographic structures of the IGF-1R kinase domain revealed that the (1248)SFYYS(1252) motif adopts a conformation tightly packed against the kinase C-lobe when Ser-1248 is in the unphosphorylated state that favors kinase activity. S1248A mutation is predicted to lock the motif in this position. In contrast, phosphorylation of Ser-1248 will drive profound structural transition of the sequence, critically affecting connection of the C terminus as well as exposing potential protein docking sites. Decreased kinase activity of a phosphomimetic S1248E mutant and enhanced kinase activity in mutants of its predicted target residue Lys-1081 support this auto-inhibitory model. Thus, the SFYYS motif controls the organization of the IGF-1R C terminus relative to the kinase domain. Its phosphorylation by GSK-3β restrains kinase activity and regulates receptor trafficking and signaling.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22685298      PMCID: PMC3431707          DOI: 10.1074/jbc.M112.385757

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

1.  RACK1-mediated integration of adhesion and insulin-like growth factor I (IGF-I) signaling and cell migration are defective in cells expressing an IGF-I receptor mutated at tyrosines 1250 and 1251.

Authors:  Patrick A Kiely; Madeline Leahy; Denise O'Gorman; Rosemary O'Connor
Journal:  J Biol Chem       Date:  2004-12-17       Impact factor: 5.157

2.  Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation.

Authors:  K P Hoeflich; J Luo; E A Rubie; M S Tsao; O Jin; J R Woodgett
Journal:  Nature       Date:  2000-07-06       Impact factor: 49.962

3.  Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor.

Authors:  Jinhua Wu; Wanqing Li; Barbara P Craddock; Kenneth W Foreman; Mark J Mulvihill; Qun-sheng Ji; W Todd Miller; Stevan R Hubbard
Journal:  EMBO J       Date:  2008-06-19       Impact factor: 11.598

4.  Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts.

Authors:  C Sell; G Dumenil; C Deveaud; M Miura; D Coppola; T DeAngelis; R Rubin; A Efstratiadis; R Baserga
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

5.  Crystal structure of the tyrosine kinase domain of the human insulin receptor.

Authors:  S R Hubbard; L Wei; L Ellis; W A Hendrickson
Journal:  Nature       Date:  1994 Dec 22-29       Impact factor: 49.962

6.  Phosphorylation of RACK1 on tyrosine 52 by c-Abl is required for insulin-like growth factor I-mediated regulation of focal adhesion kinase.

Authors:  Patrick A Kiely; George S Baillie; Robert Barrett; Deirdre A Buckley; David R Adams; Miles D Houslay; Rosemary O'Connor
Journal:  J Biol Chem       Date:  2009-05-07       Impact factor: 5.157

7.  Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment.

Authors:  Scott C Mayer; Annette L Banker; Frank Boschelli; Li Di; Mark Johnson; Cynthia Hess Kenny; Girija Krishnamurthy; Kristina Kutterer; Franklin Moy; Susan Petusky; Malini Ravi; Diane Tkach; Hwei-Ru Tsou; Weixin Xu
Journal:  Bioorg Med Chem Lett       Date:  2008-04-25       Impact factor: 2.823

Review 8.  Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions.

Authors:  A Gualberto; M Pollak
Journal:  Oncogene       Date:  2009-07-06       Impact factor: 9.867

9.  Does GSK-3 provide a shortcut for PI3K activation of Wnt signalling?

Authors:  Daniel Voskas; Ling S Ling; James R Woodgett
Journal:  F1000 Biol Rep       Date:  2010-11-24

10.  Effects of somatic mutations in the C-terminus of insulin-like growth factor 1 receptor on activity and signaling.

Authors:  Barbara P Craddock; W Todd Miller
Journal:  J Signal Transduct       Date:  2012-06-14
View more
  10 in total

Review 1.  Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.

Authors:  Eleonore Beurel; Steven F Grieco; Richard S Jope
Journal:  Pharmacol Ther       Date:  2014-11-27       Impact factor: 12.310

2.  How Protein Kinase A Activates Canonical Tyrosine Kinase Signaling Pathways To Promote Granulosa Cell Differentiation.

Authors:  Nathan C Law; Elyse M Donaubauer; Anthony J Zeleznik; Mary Hunzicker-Dunn
Journal:  Endocrinology       Date:  2017-07-01       Impact factor: 4.736

Review 3.  IGF-1 Receptor and Adhesion Signaling: An Important Axis in Determining Cancer Cell Phenotype and Therapy Resistance.

Authors:  Orla T Cox; Sandra O'Shea; Emilie Tresse; Milan Bustamante-Garrido; Ravi Kiran-Deevi; Rosemary O'Connor
Journal:  Front Endocrinol (Lausanne)       Date:  2015-07-03       Impact factor: 5.555

4.  Celecoxib inhibits insulin-like growth factor 1 induced growth and invasion in non-small cell lung cancer.

Authors:  Chen-Hui Liu; Hong-Guang Bao; Ya-Li Ge; Shu-Kui Wang; Yan Shen; Li Xu
Journal:  Oncol Lett       Date:  2013-03-29       Impact factor: 2.967

5.  Impact of phosphorylated insulin-like growth factor-1 receptor on the outcome of breast cancer patients and the prognostic value of its alteration during neoadjuvant chemotherapy.

Authors:  Liang Li; Shuchen Liu; Liyuan Liu; Zhongbing Ma; Man Feng; Chunmiao Ye; Wenzhong Zhou; Yongjiu Wang; Lu Liu; Fei Wang; Lixiang Yu; Fei Zhou; Yujuan Xiang; Shuya Huang; Qinye Fu; Qiang Zhang; Dezong Gao; Zhigang Yu
Journal:  Exp Ther Med       Date:  2018-08-07       Impact factor: 2.447

6.  Modeling cell line-specific recruitment of signaling proteins to the insulin-like growth factor 1 receptor.

Authors:  Keesha E Erickson; Oleksii S Rukhlenko; Md Shahinuzzaman; Kalina P Slavkova; Yen Ting Lin; Ryan Suderman; Edward C Stites; Marian Anghel; Richard G Posner; Dipak Barua; Boris N Kholodenko; William S Hlavacek
Journal:  PLoS Comput Biol       Date:  2019-01-17       Impact factor: 4.475

7.  Insulin-like growth factor-binding proteins play a significant role in the molecular response to imatinib in chronic myeloid leukemia patients.

Authors:  Yingli Ren; Shihong Yin; Ya Lin; Xiucai Xu
Journal:  Exp Ther Med       Date:  2019-12-20       Impact factor: 2.447

8.  Defining the epitope of a blood-brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor.

Authors:  Joey Sheff; Ping Wang; Ping Xu; Melanie Arbour; Luke Masson; Henk van Faassen; Greg Hussack; Kristin Kemmerich; Eric Brunette; Danica Stanimirovic; Jennifer J Hill; John Kelly; Feng Ni
Journal:  Sci Rep       Date:  2021-02-19       Impact factor: 4.996

Review 9.  The Role of GSK-3β in the Regulation of Protein Turnover, Myosin Phenotype, and Oxidative Capacity in Skeletal Muscle under Disuse Conditions.

Authors:  Timur M Mirzoev; Kristina A Sharlo; Boris S Shenkman
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

Review 10.  Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation.

Authors:  Leonard Girnita; Claire Worrall; Shin-Ichiro Takahashi; Stefan Seregard; Ada Girnita
Journal:  Cell Mol Life Sci       Date:  2013-11-26       Impact factor: 9.261

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.